R&D Sponsored 12 Questions with Faruk Uzman Find out more about Faruk Uzman, VP EMEA at Boston Scientific, in a new 12 Questions With.
R&D Sponsored 12 Questions with Lucy Walker Lucy Walker is the Head of Medical Operations at the growing medical consultancy LUCENT Biopharma. Find out more in a new 12 Questions With.
Sales & Marketing Sponsored 12 Questions with Steve Sanghera Steve Sanghera is the CEO and co-founder of Inventus.
Sales & Marketing Sponsored 12 Questions with Dermot Kenny Dermot Kenny, who leads STEM and Research Partnership at Inizio Advisory, shares his journey from bench scientist to CEO in a new 12 Questions With.
Sales & Marketing Sponsored 12 Questions with Jim Sage Jim Sage is a seasoned global pharmaceutical executive with extensive marketing, commercial, and leadership experience across major therapeutic areas.
R&D Sponsored 12 Questions with Phil Davey Phil Davey is the General Manager at Alnylam for the UK, Ireland, the Nordics, and Canada.
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
